GENEVA--(BUSINESS WIRE)--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and ...

Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, designed to hinder the SARS-CoV-2 virus’s ability to replicate. Clinical ...

More than two years after the World Health Organization (WHO) declared an end to the emergency phase of the Covid-19 pandemic ...

Late-stage trial data suggest that a new COVID-flu vaccine offers good protection against both infections, but experts expect the shot's approval may be delayed. When you purchase through links on our ...

AIM ImmunoTech Inc. announced progress in its clinical development of Ampligen® (rintatolimod), particularly in addressing critical unmet medical needs in areas like pancreatic cancer and Long-COVID.

The BHC-202 3-arm study comparing two dose levels of the valacyclovir/celecoxib combination vs placebo over 12 weeks to treat symptoms of LC is being conducted by the Bateman Horne Center (“BHC”) via ...

Patients in the ratutrelvir arm received ratutrelvir 600 mg orally once daily for 10 days, while patients in the comparator arm received PAXLOVID™ administered as nirmatrelvir 300 mg plus ritonavir ...

Moderna’s next-gen COVID vaccine notched a higher immune response than its licensed counterpart, passing a phase 3 test. No data accompanied the company’s announcement Tuesday, with Moderna saying ...